Top

Published in:

Open Access 01-02-2008 | Educational Feature

Anemia in children with chronic kidney disease

Authors: Susan M. Koshy, Denis F. Geary

Published in: Pediatric Nephrology | Issue 2/2008

Abstract

Anemia is a common feature of chronic kidney disease, but the management of anemia in children is complex. Erythropoietin and supplemental iron are used to maintain hemoglobin levels. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) clinical practice guidelines for the management of anemia specifically in children were recently published. Pediatric nephrologists are encouraged to use current clinical practice guidelines and best evidence in conjunction with their clinical experience to optimally manage patients with anemia.

Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D (1999) Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34:125–134PubMed

Morris KP, Skinner JR, Hunter S, Coulthard MG (1994) Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia? Arch Dis Child 71:119–122PubMed

Morris KP, Sharp J, Watson S, Coulthard MG (1993) Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child 69:580–586PubMed

Jabs K (1996) The effects of recombinant human erythropoietin on growth and nutritional status. Pediatr Nephrol 10:324–327PubMed

Chavers BM, Roberts TL, Herzog CA, Collins AJ, St Peter WL (2004) Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients. Kidney Int 65:266–273PubMedCrossRef

Wong H, Mylrea K, Feber J, Drukker A, Filler G (2006) Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70:585–590PubMed

K/DOQI; National Kidney Foundation (2006) III Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Children. Am J Kidney Dis 47(Suppl 3):S86–108

Behrman RE, Kliegman R, Jenson HB (2000) Nelson textbook of pediatrics, 16th edn. W.B. Saunders Company, Collingwood, Ontario

Beutler E, Waalen J (2006) The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration. Blood 107:1747–1750PubMedCrossRef

10.

Hollowell JG, Van Assendelft OW, Gunter EW, Lewis BG, Najjar M, Pfeiffer C (2005) Hematological and iron-related analytes – reference data for persons aged 1 year and over: United States, 1988–1994. National Center for Health Statistics. Vital Health Stat 11:1–156

11.

McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW (1984) Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437–444PubMedCrossRef

12.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73–78PubMedCrossRef

13.

Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T (1985) Isolation and characterization of genomic cDNA clones of human erythropoietin. Nature 313:806–810PubMedCrossRef

14.

Lin FK, Suggs S, Lin CH, Browne JK, Smailing R, Egric JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai PH, Goldwasser E (1985) Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580–7584PubMedCrossRef

15.

Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 228:1–14

16.

Koury MJ, Bondurant MC (1992) The molecular mechanism of molecular erythropoietin production. Eur J Biochem 210:649–666PubMedCrossRef

17.

Donnelly S (2001) Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis 38:415–425PubMed

18.

Besarab A, Frinak S, Yee J (1999) An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 10:2029–2043PubMed

19.

Ly J, Marticorena R, Donnelly S (2004) Red blood cell survival in chronic renal failure. Am J Kidney Dis 44:715–719PubMedCrossRef

20.

Muller-Wiefel DE, Sinn H, Gilli G, Scharer K (1977) Hemolysis and blood loss in children with chronic renal failure. Clin Nephrol 8:481–486PubMed

21.

Gillespie RS, Wolf FM (2004) Iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 19:662–666PubMedCrossRef

22.

Morgan HE, Gautam M, Geary DF (2001) Maintenance intravenous iron therapy in pediatric hemodialysis patients. Pediatr Nephrol 16:779–783PubMedCrossRef

23.

Andrews NC (1999) Disorders of iron metabolism. N Engl J Med 341:1986–1995PubMedCrossRef

24.

Macdougall IC, Cooper AC (2002) Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17[Suppl 11]:39–43PubMed

25.

Pereira BJ (1995) Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis. Nephrol Dial Transplant 10[Suppl 7]:27–32PubMed

26.

Nomura S, Ogawa Y, Osawa G, Katagiri M, Harada T, Nagahana H (1996) Myelofibrosis secondary to renal osteodystrophy. Nephron 72:683–687PubMed

27.

Rosenlof K, Fyhrquist F, Tenhunen R (1990) Erythropoietin, aluminium, and anaemia in patients on hemodialysis. Lancet 335:247–249PubMedCrossRef

28.

Roger SD, Macdougall IC, Thuraisingham RC, Raine AE (1991) Erythropoietin in anemia of renal failure in sickle cell disease. N Engl J Med 325:1175–1176PubMedCrossRef

29.

Cheng IK, Lu HB, Wei DC, Cheng SW, Chan CY, Lee FC (1993) Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients. Am J Nephrol 13:142–148PubMed

30.

Hess E, Sperschneider H, Stein G (1996) Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? Nephrol Dial Transplant 11:749–751PubMed

31.

Lu R, Foerster J, Lukens J, Paraskevas F, Greer JP (1999) Wintrobe’s clinical hematology, 10th edn. Lippincott Williams and Wilkins, Philadelphia

32.

Henry JB (1996) Methods hematology: basic methodology in clinical diagnosis and management by laboratory methods, 19th edn. Saunders, Philadelphia

33.

Holt JT, DeWandler MJ, Aevan DA (1982) Spurious elevation of electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia. Am J Clin Pathol 77:561–567PubMed

34.

Adamson JW (1999) Normal iron physiology. Semin Dialysis 12:219–223CrossRef

35.

Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK (1996) The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 7:2654–2657PubMed

36.

Mittal S, Maesaka JK, Fishbane S (1999) Diagnosis of iron deficiency in end stage renal disease. Semin Dial 12:231–234CrossRef

37.

Frankenfield DL, Neu AM, Warady BA, Fivush BA, Johnson CA, Brem AS (2003) Anemia in pediatric hemodialysis patients: results from the 2001 ESRD Clinical Performance Measures Project. Kidney Int 64:1120–1124PubMedCrossRef

38.

Braun J (1999) Erythrocyte zinc protoporphyrin. Kidney Int 55[Suppl 69]:S57–S60CrossRef

39.

Thomas C, Thomas L (2002) Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 48:1066–1076PubMed

40.

Chiang WC, Tsai TJ, Chen YM, Lin SL, Hsieh BS (2002) Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients. Clin Nephrol 58:363–369PubMed

41.

Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Coates PM (1986) Effective human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175–1178PubMedCrossRef

42.

Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW (1989) Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158–163PubMedCrossRef

43.

Casati S, Passerini P, Campise MR, Graziani G, Cesana E, Ponticelli C (1987) Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis. N Engl J Med 295:1017–1020

44.

Sinai-Trieman L, Salusky IB, Fine RN (1989) Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis. J Pediatr 114:550–554PubMedCrossRef

45.

Offner G, Hoyer PF, Latta K, Winkler L, Brodehl J, Scigalla P (1990) One year’s experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis. Pediatr Nephrol 5:498–500CrossRef

46.

Provenzano R, Bhaduri S, Singh AK (2005) Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the prompt study. Clin Nephrol 2:113–123CrossRef

47.

North American Pediatric Renal Transplant Cooperative Study Registry Report (2004) https://web.emmes.com/study/ped/annlrept/annlrept.html

48.

Port RE, Kiepe D, Van Guilder M, Jelliffe RW, Mehls O (2004) Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage. Clin Pharmacokinet 43:57–70PubMedCrossRef

49.

MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J (1999) Pharmacokinetics of novel erythropoesis-stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392–2395PubMed

50.

Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 11:933–937CrossRef

51.

Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C (2002) Randomized control trial of Darbepoetin Alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110–118PubMedCrossRef

52.

Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ (2001) Novel erythropoesis-stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741–747PubMedCrossRef

53.

DePalo P, Giordanno M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with Darbepoetin Alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 3:337–340

54.

Geary DF, Keating LE, Vigneux A, Stevens D, Hébert D, Harvey EA (2005) Darbepoetin Alfa (Aranesp) in children with chronic renal failure. Kidney Int 4:1759–1765CrossRef

55.

Durkan AM, Keating LE, Vigneux A, Geary DF (2006) The use of Darbepoetin in infants with chronic renal impairment. Pediatr Nephrol 5:694–697CrossRef

56.

Casadevall N, Nataf J, Viron B, Colta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P (2002) Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:46–475CrossRef

57.

Bennett CL, Cournoyer D, Carson KR, Rossert J, Luminari S, Evens AM (2005) Long term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin; a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106:3343–3347PubMedCrossRef

58.

Casadeall N, Eckardt KU, Rossert J (2005) Epoetin induced autoimmune pure red cell aplasia. J Am Soc Nephrol 16:S67–S69CrossRef

59.

Fishbane S, Maesaka JK (1997) Iron management in end-stage renal disease. Am J Kidney Dis 29:319–333PubMed

60.

Fishbane S (1998) Iron treatment: impact of safety issues. Am J Kidney Dis 32[Suppl 4]:S152–S156PubMed

61.

Jensen RT (2006) Consquences of long-term proton pump blockage: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98:4–19PubMedCrossRef

62.

Ruiz-Jaramillo Mde L, Guizar-Mendoza JM, Gutierrez-Navarro Mde J, Dubey-Ortega LA, Amador-Licona N (2004) Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. Pediatr Nephrol 19:77–81PubMedCrossRef

63.

Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara (2004) Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:655–661PubMedCrossRef

64.

Warady BA, Zobrist RH, Wu J, Finan E (2005) Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20:1320–1327PubMedCrossRef

65.

Novey HS, Pahl M, Haydik I, Vaziri ND (1994) Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 72:224–228PubMed

66.

Agarwal R, Vasvada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65:2279–2289PubMedCrossRef

67.

Fletes R, Lazarus M, Gage J, Chertow GM (2001) Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 37:743–749PubMedCrossRef

68.

Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J (1996) The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529–534PubMed

69.

Faich G, Strobos J (1999) Sodium ferric gluconate complex in sucrose: saferintravenous iron therapy than iron dextrans. Am J Kidney Dis 33:464–470PubMed

70.

Berard E, Iordache A (1992) Effect of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: about two cases. Nephron 62:368–369PubMedCrossRef

71.

Lilien MR, Duran M, Quak JM, Frankhuisen JJ, Schroder CH (2000) Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis. Pediatr Nephrol 15:17–20PubMedCrossRef

72.

Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C (1995) Resistance to erythro- poietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10[Suppl 6]:44–47PubMed

73.

Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, Grande J (2003) Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J Nephrol 16:703–709PubMed

74.

Keven K, Kutlay S, Nergizoglu G, Erturk S (2003) Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41:1233–1239PubMedCrossRef

75.

Bamgbola OF, Kaskel F (2005) Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol 20:1622–1629PubMedCrossRef

76.

Rossert J, Fouqueray B, Boffa JJ (2003) Anemia management and the delay of chronic renal failure progression. J Am Soc Nephrol 14[Suppl 2]:S173–S177PubMedCrossRef

77.

Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF (2000) Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 14:898–902PubMedCrossRef

78.

Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055–1062PubMedCrossRef

79.

Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017–1023PubMedCrossRef

80.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Eng J Med 339:584–590CrossRef

81.

Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D (2005) Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16:2180–2189PubMedCrossRef

Title: Anemia in children with chronic kidney disease
Authors: Susan M. Koshy
Denis F. Geary
Publication date: 01-02-2008
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 2/2008
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-006-0381-2

At a glance: The STEP trials

Springer Medicine

Anemia in children with chronic kidney disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2008

Diet does not explain the high prevalence of dyslipidaemia in paediatric renal transplant recipients

Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker

CORRECTION

Homotoxicological remedies versus desmopressin versus placebo in the treatment of enuresis: a randomised, double-blind, controlled trial

A milder variant of Pierson syndrome

Influence of N-acetylcysteine on renal toxicity of cadmium in rats